Alverine-citrate-NSC-35459-DataSheet-生命科學(xué)試劑-MedChemExpress_第1頁(yè)
Alverine-citrate-NSC-35459-DataSheet-生命科學(xué)試劑-MedChemExpress_第2頁(yè)
Alverine-citrate-NSC-35459-DataSheet-生命科學(xué)試劑-MedChemExpress_第3頁(yè)
全文預(yù)覽已結(jié)束

下載本文檔

版權(quán)說(shuō)明:本文檔由用戶提供并上傳,收益歸屬內(nèi)容提供方,若內(nèi)容存在侵權(quán),請(qǐng)進(jìn)行舉報(bào)或認(rèn)領(lǐng)

文檔簡(jiǎn)介

1、Hotline: 400-820-3792Inhibitors Agonists Screening Librarieswww.MedChemEAlverine citrateCat. No.: HY-B0500CAS No.: 5560-59-8Synonyms: NSC 35459分式: CHNO分量: 473.56作靶點(diǎn): 5-HT Receptor作通路: GPCR/G Protein; Neuronal Signaling儲(chǔ)存式: Powder -20C 3 years4C 2 yearsIn solvent -80C 6 months-20C 1 month溶解性數(shù)據(jù)體外實(shí)驗(yàn) DM

2、SO : 22 mg/mL (46.46 mM; Need ultrasonic and warming)Mass Solvent1 mg 5 mg 10 mg Concentration制備儲(chǔ)備液1 mM 2.1117 mL 10.5583 mL 21.1166 mL5 mM 0.4223 mL 2.1117 mL 4.2233 mL10 mM 0.2112 mL 1.0558 mL 2.1117 mL請(qǐng)根據(jù)產(chǎn)品在不同溶劑中的溶解度,選擇合適的溶劑配制儲(chǔ)備液,并請(qǐng)注意儲(chǔ)備液的保存式和期限。BIOLOGICAL ACTIVITY物活性 Alverine citrate5-HT1A 受體的個(gè)拮抗

3、劑,其 IC50 值為101 nM。IC50 & Target 5-HT1A Receptor101 nM (IC50)體外研究Alverine is a drug used for functional gastrointestinal disorders. Alverine acts directly on the muscle in the1/2 Master of Small Molecules 您邊的抑制劑師www.MedChemEgut, causing it to relax. Alverine Citrate (20 mg/kg) suppresses the effect o

4、f 5-HTP, but not that of 8-OH-DPAT. However, when injected intracerebroventricularly (75 g/rat) alverine citrate reduces 8-OH-DPAT-induced enhancement of rectal distension-induced abdominal contractions. In-vitro binding studies revealthat Alverine citrate has a high affinity for 5-HT1A receptors an

5、d a weak affinity for 5-HT3 and 5-HT4subtypes 1. Alverine may increase Ca influx during action potentials due to inhibition of the inactivation of L-type Ca channels, but may also suppress evoked activity by inhibiting the sensitivity of contractile proteins toCa2+ 2.REFERENCES1. Coelho, A.M., et al

6、., Rectal antinociceptive properties of alverine citrate are linked to antagonism at the 5-HT1A receptor subtype. JPharm Pharmacol, 2001. 53(10): p. 1419-26.2. Hayase, M., et al., Evolving mechanisms of action of alverine citrate on phasic smooth muscles. Br J Pharmacol, 2007. 152(8): p. 1228-38.McePdfHeightCaution: Product has not been fully validated for medical applications.For research use only.Tel: 40

溫馨提示

  • 1. 本站所有資源如無(wú)特殊說(shuō)明,都需要本地電腦安裝OFFICE2007和PDF閱讀器。圖紙軟件為CAD,CAXA,PROE,UG,SolidWorks等.壓縮文件請(qǐng)下載最新的WinRAR軟件解壓。
  • 2. 本站的文檔不包含任何第三方提供的附件圖紙等,如果需要附件,請(qǐng)聯(lián)系上傳者。文件的所有權(quán)益歸上傳用戶所有。
  • 3. 本站RAR壓縮包中若帶圖紙,網(wǎng)頁(yè)內(nèi)容里面會(huì)有圖紙預(yù)覽,若沒(méi)有圖紙預(yù)覽就沒(méi)有圖紙。
  • 4. 未經(jīng)權(quán)益所有人同意不得將文件中的內(nèi)容挪作商業(yè)或盈利用途。
  • 5. 人人文庫(kù)網(wǎng)僅提供信息存儲(chǔ)空間,僅對(duì)用戶上傳內(nèi)容的表現(xiàn)方式做保護(hù)處理,對(duì)用戶上傳分享的文檔內(nèi)容本身不做任何修改或編輯,并不能對(duì)任何下載內(nèi)容負(fù)責(zé)。
  • 6. 下載文件中如有侵權(quán)或不適當(dāng)內(nèi)容,請(qǐng)與我們聯(lián)系,我們立即糾正。
  • 7. 本站不保證下載資源的準(zhǔn)確性、安全性和完整性, 同時(shí)也不承擔(dān)用戶因使用這些下載資源對(duì)自己和他人造成任何形式的傷害或損失。

評(píng)論

0/150

提交評(píng)論